Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Diabetic Foot Ulcer: full-pipeline trial registry
42 of 68 indexed Diabetic Foot Ulcer trials are currently recruiting.
Corpus placement: #203 of 28,707 conditions by registered trial count.
68 US clinical trials · 42 currently recruiting · #203 of 28,707 conditions by registered trial count
Diabetic Foot Ulcer: 68 US clinical trials tracked, 42 recruiting.
Diabetic Foot Ulcer is the subject of 68 registered US clinical trials on ClinicalTrials.gov, 42 of them currently open to new participants. 9 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is Applied Biologics, running 3 of these trials.
Enrollment posture brief
Registry condition diabetic-foot-ulcer
OPEN 42 | RECR 62% | LATE 9 | EARLY 8 | RANK #203 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Pregnancy, High Risk (62% recruiting · 21 trials)
Diabetic Foot Ulcer lists 42 open slots (62% of 68 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Diabetic Foot Ulcer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Diabetic Foot Ulcer is recruiting above its size-band peers.
42 of 68 indexed trials (61.8%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Diabetic Foot Ulcer trials is spread across many organizations.
Applied Biologics accounts for 3 of 68 trials (4.4%). 52 distinct sponsors appear on at least one study for this condition label.
-
Typical Diabetic Foot Ulcer enrolment sits around 120 participants.
Median target enrolment is 120 among the 68 trials that report a genuine target (sentinel values excluded). 28 of those (41.2%) plan for fewer than 100 participants.
-
Diabetic Foot Ulcer research is mostly interventional.
61 interventional and 7 observational studies make up this index (89.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
68 total, page 2 of 2
DermACELL in Subjects With Chronic Wounds of the Lower Extremities
LifeNet Health
NCT01970163
Clinical Study Evaluating Symphony™ Versus Standard of Care in the Treatment of Non-Healing Diabetic Foot Ulcers
Aroa Biosurgery Limited
NCT06035536
Diabetic Foot Ulcers-Comparing Transforming Powder to Standard of Care
ULURU
NCT05046158
VA MERIT: A Comparative Efficacy Study: Treatment of Non-Healing Diabetic
VA Office of Research and Development
NCT01450943
AMNIOEXCEL® Plus vs A Marketed Comparator vs SOC in the Management of Diabetic Foot Ulcers
Integra LifeSciences Corporation
NCT03547635
Implementation of Telemedicine for Patient With Lower Extremity Wounds
University of California, Davis
NCT04440839
Phase 2a Multi-Center Prospective, Randomized Trial to Evaluate the Safety & Efficacy of Topical PEP-TISSEEL for Diabetic Foot Ulcers (DFU)
Rion
NCT06319287
Diabetic Foot Ulcer (DFU) Rapid Pathogen Identification
University of Michigan
NCT06569238
Evaluation Of An Advanced Borderless Dressing
Smith & Nephew
NCT03146845
Comparative Effectiveness of Two Acellular Matrices (Dermacell vs. Integra) for Management of Deep Diabetic Foot Ulcers
Baylor College of Medicine
NCT03476876
The Effects of Nutrition Supplementation and Education on the Healing of Diabetic Foot Ulcer (DFU)
Florida State University
NCT04055064
Evaluating The Efficacy Of A Keratin Graft In Treating Non-Healing Diabetic Foot Ulcers
ProgenaCare Global
NCT05797285
Comparative Study of Amniotic Membrane Wound Graft In the Management of Diabetic Foot Ulcers
MiMedx Group
NCT01552499
Clinical Study to Compare Two Skin Substitute Categories for Their Effectiveness to Treat Diabetic Foot Ulcers
Encoll
NCT06557122
Multi Center Site , Controlled Trial Comparing a Bioengineered Skin Substitute to a Human Skin Allograft
Solsys Medical
NCT01676272
Topical PluroGel PN for the Treatment of Mildly Infected Diabetic Foot Ulcers
PluroGen Therapeutics
NCT02119754
Pilot Study of PHOENIX Wound Matrix® Impact on Chronic DFU Wound Microbiome
RenovoDerm
NCT04437537
Evaluating Clinical Acceptance of a NPWT Wound Care System
Medela
NCT03670225
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 6 |
| Phase 3 | 2 |
| Phase 4 | 7 |
Top Sponsors
Named interventions
Most-linked intervention names on Diabetic Foot Ulcer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Diabetic Foot Ulcer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Diabetic Foot Ulcer page
68 registered trials, 42 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 42 Diabetic Foot Ulcer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Applied Biologics sponsors the most Diabetic Foot Ulcer trials on record, review their full trial history before evaluating a specific study. See Applied Biologics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Diabetic Foot Ulcer condition card totals 68 registered trials; most-linked intervention Standard of Care; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.